6. Conclusion
Our analysis provides valuable insights into the safety profiles of
pirfenidone and nintedanib in real-world practice. The findings
emphasize the importance of monitoring and managing specific ADRs and
highlight the need for continued pharmacovigilance efforts to ensure
patient safety in the long-term use of these drugs for IPF treatment.